Allogene Therapeutics ALLO Lease Liability Payments - Due Year Three
Lease Liability Payments - Due Year Three at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's lease liability payments - due year three.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's lease liability payments - due year three?
- Allogene Therapeutics (ALLO) reported lease liability payments - due year three of $15.44M in Q1 2026.
- How has Allogene Therapeutics's lease liability payments - due year three changed year-over-year?
- Allogene Therapeutics's lease liability payments - due year three increased by 9.6% year-over-year, from $14.08M to $15.44M.
- What does lease liability payments - due year three mean?
- The contractual cash obligations for operating and finance leases due in the third year following the balance sheet date. This metric helps in mapping out the long-term fixed cost profile of the company. It is essential for evaluating the sustainability of lease-related cash outflows over a multi-year horizon.